MARKET

HAE

HAE

Haemonetics Corp Mass
NYSE

Real-time Quotes | Nasdaq Last Sale

60.77
-0.46
-0.75%
After Hours: 60.77 0 0.00% 16:01 05/24 EDT
OPEN
60.72
PREV CLOSE
61.23
HIGH
61.51
LOW
60.25
VOLUME
346.73K
TURNOVER
0
52 WEEK HIGH
75.34
52 WEEK LOW
43.50
MARKET CAP
3.11B
P/E (TTM)
139.19
1D
5D
1M
3M
1Y
5Y
Insider Sell: Haemonetics
MT Newswires · 1d ago
Here's Why Investors Should Retain Haemonetics (HAE) For Now
Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.
Zacks · 1d ago
Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up
Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.
Zacks · 05/11 15:12
--Raymond James Lowers Haemonetics Price Target to $63 From $66, Maintains Outperform Rating
MT Newswires · 05/11 12:18
--Barrington Raises Haemonetics Price Target to $77 From $71, Maintains Outperform Rating
MT Newswires · 05/11 11:09
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 05/10 16:01
Biohaven, AdaptHealth top healthcare gainers; Bausch Health, GoodRx lead losers' pack
Gainers: Biohaven Pharmaceutical (BHVN) +71%. AdaptHealth (AHCO) +31%. Evaxion Biotech (EVAX) +25%. Assertio (ASRT) +22%. Haemonetics (HAE) +16%. Losers: Bausch Health (BHC) -26%. GoodRx (GDRX) -24%. Akanda (AKAN) -21%. Novavax (NVAX) -12%. Blue Water Vacc...
Seekingalpha · 05/10 14:02
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) delivered earnings and revenue surprises of 8.33% and 2.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 11:35
More
No Data
Learn about the latest financial forecast of HAE. Analyze the recent business situations of Haemonetics Corp Mass through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

14.29%Strong Buy
42.86%Buy
42.86%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average HAE stock price target is 70.17 with a high estimate of 80.00 and a low estimate of 60.00.
High80.00
Average70.17
Low60.00
Current 60.77
EPS
Actual
Estimate
0.210.420.630.84
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Institutional Holdings
Institutions: 409
Institutional Holdings: 57.03M
% Owned: 111.58%
Shares Outstanding: 51.11M
TypeInstitutionsShares
Increased
96
6.53M
New
26
730.16K
Decreased
80
3.38M
Sold Out
43
2.37M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.84%
Healthcare Equipment & Supplies
-0.35%
Key Executives
Non-Executive Chairman/Independent Director
Ellen Zane
President/Chief Executive Officer/Director
Christopher Simon
Chief Financial Officer/Executive Vice President
James D'arecca
Executive Vice President/Chief Technology Officer
Anila Lingamneni
Executive Vice President/General Counsel
Michelle Basil
Senior Vice President
Josep Llorens
Director
Lloyd Johnson
Independent Director
Robert Abernathy
Independent Director
Catherine Burzik
Independent Director
Michael Coyle
Independent Director
Charles Dockendorff
Independent Director
Mark Kroll
Independent Director
Claire Pomeroy
No Data
No Data
About HAE
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. It markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.

Webull offers kinds of Haemonetics Corporation stock information, including NYSE:HAE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HAE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HAE stock methods without spending real money on the virtual paper trading platform.